Kurma investing new fund; Kailera advancing obesity assets with $400M

Kurma Partners is building a diverse portfolio of life sciences companies with its new Biofund IV, toward which it has raised the first €140 million ($154.5 million) of its €250 million goal.

The European VC has already made three investments from the new vehicle, which is designed for distribution among 16-20 start-ups. The firm will continue to create new start-ups from scratch and join syndicates at other stages. It will also continue to invest in maturing companies out of its Growth Opportunities Fund...